BRPI0923886A2 - "uso de cloreto de amônio em terapia" - Google Patents

"uso de cloreto de amônio em terapia"

Info

Publication number
BRPI0923886A2
BRPI0923886A2 BRPI0923886-7A BRPI0923886A BRPI0923886A2 BR PI0923886 A2 BRPI0923886 A2 BR PI0923886A2 BR PI0923886 A BRPI0923886 A BR PI0923886A BR PI0923886 A2 BRPI0923886 A2 BR PI0923886A2
Authority
BR
Brazil
Prior art keywords
therapy
ammonium chloride
ammonium
chloride
Prior art date
Application number
BRPI0923886-7A
Other languages
English (en)
Inventor
Diamantis Kiassos
Alessandro Gagnoni
Original Assignee
Rainbow Pharmaceutical S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rainbow Pharmaceutical S A filed Critical Rainbow Pharmaceutical S A
Publication of BRPI0923886A2 publication Critical patent/BRPI0923886A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0923886-7A 2009-01-02 2009-12-29 "uso de cloreto de amônio em terapia" BRPI0923886A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/348,220 US8840934B2 (en) 2009-01-02 2009-01-02 Uses of ammonium chloride
PCT/EP2009/067993 WO2010076323A1 (en) 2009-01-02 2009-12-29 Use of ammonium chloride in therapy

Publications (1)

Publication Number Publication Date
BRPI0923886A2 true BRPI0923886A2 (pt) 2015-07-28

Family

ID=41649998

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923886-7A BRPI0923886A2 (pt) 2009-01-02 2009-12-29 "uso de cloreto de amônio em terapia"

Country Status (15)

Country Link
US (1) US8840934B2 (pt)
EP (1) EP2373320A1 (pt)
JP (1) JP2012514583A (pt)
KR (1) KR20110101125A (pt)
CN (1) CN102209549A (pt)
AP (1) AP3436A (pt)
AU (1) AU2009334784B2 (pt)
BR (1) BRPI0923886A2 (pt)
CA (1) CA2740521A1 (pt)
EA (1) EA024723B1 (pt)
IL (1) IL212208A0 (pt)
MX (1) MX2011004189A (pt)
NZ (1) NZ592077A (pt)
WO (1) WO2010076323A1 (pt)
ZA (1) ZA201102416B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
US4346082A (en) * 1980-01-04 1982-08-24 The Vinoxen Company Method of employing therapeutic composition comprising ammonium or substituted ammonium compounds for treatment of alcoholism
EP0095833A3 (en) * 1982-05-03 1984-12-27 Roland Vilagines Method of preventing infection by viropexis-penetrating viruses
NL8401782A (nl) 1984-06-04 1986-01-02 Jan Willem Bins Therapeutisch preparaat met ammoniumnitraat als werkzame stof.
NZ231236A (en) 1988-11-11 1992-07-28 Manrex Australia Pty Ltd Assembly for blister package
US5275828A (en) * 1989-11-08 1994-01-04 Hooper Oswald E Treatment and/or a method of treating equine viral and bacterial infections
AU642173B2 (en) * 1989-11-08 1993-10-14 Oswald Edmonds Hooper Improvements in or relating to a treatment and or a method of treating
JPH0789862A (ja) * 1990-05-29 1995-04-04 Toyobo Co Ltd 抗炎症性、免疫抑制性および鎮痛性組成物、およびこれらの組成物を用いた自己免疫疾患の治療方法
WO1996032952A1 (en) 1995-04-21 1996-10-24 Oswald Edmonds Hooper Caffeine composition as medicament and use thereof
SE9200502D0 (sv) 1992-02-20 1992-02-20 Astra Ab Novel antioxidants
MX9503783A (es) 1995-09-04 1997-03-29 William C Stacey Combinaciones de compuestos de cloruro de amonio para el tratamiento de infecciones virales.
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
GR1003980B (el) 2001-04-20 2002-09-03 Ιωαννου Διαμαντης Κιασσος Νεα χρηση του χλωριουχου αμμωνιου για τη θεραπεια των ενδοηπατικων χολοστασεων οφειλομενων εις δυσπραγια του ηπατικου κυτταρου
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
GR20020100405A (el) 2002-09-12 2004-05-24 Διαμαντης Ιωαννου Κιασσος Νεα χρηση του nh4 cl για την θεραπεια της ηπατικης ινωσεως νεκρωσεως και εγκεφαλοπαθιας οξειας και χρονιας ηπατικης ανεπαρκειας. νεα χρηση του nh4 cl για την θεραπεια της υπερχολερυθριναιμιας, υπερτρασανεμιας προκιρρωτικων και κιρρωτικων καταστασεων του ηπατος, ως επισης για την προληψη της μετατροπης των ως ανω νοσηματων εις νεοπλασματα του ηπατος.
CA2617941C (en) 2004-08-23 2012-07-24 Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co. Kg Psychostimulant containing pharmaceutical composition
EP1906934A4 (en) 2005-07-14 2012-03-07 Franco Folli DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20070251852A1 (en) * 2006-04-28 2007-11-01 David Purdy Multiple medication package
PT1875918E (pt) 2006-07-03 2013-12-26 Rainbow Pharmaceutical Sa Nova utilização de cloreto de amónio para a terapia de insuficiência e necrose hepática total ou parcial

Also Published As

Publication number Publication date
AU2009334784A1 (en) 2010-07-08
EA024723B1 (ru) 2016-10-31
JP2012514583A (ja) 2012-06-28
MX2011004189A (es) 2011-08-12
AP2011005798A0 (en) 2011-08-31
AU2009334784B2 (en) 2014-01-16
EA201101036A1 (ru) 2012-01-30
NZ592077A (en) 2013-05-31
WO2010076323A1 (en) 2010-07-08
CA2740521A1 (en) 2010-07-08
IL212208A0 (en) 2011-06-30
CN102209549A (zh) 2011-10-05
ZA201102416B (en) 2012-06-27
AP3436A (en) 2015-10-31
US8840934B2 (en) 2014-09-23
US20100173020A1 (en) 2010-07-08
EP2373320A1 (en) 2011-10-12
KR20110101125A (ko) 2011-09-15

Similar Documents

Publication Publication Date Title
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
PT3042910T (pt) 2'-espiro-nucleósidos para utilização na terapia da hepatite c
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
SMT201400164B (it) Morfolino pirimidine e loro uso in terapia
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
HK1146596A1 (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BR302012003093S1 (pt) "configuração aplicada em caixa de relogio"
EP2268281A4 (en) THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
BRPI0817190A2 (pt) Uso de nanopartículas em explosivos
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
BRPI0923886A2 (pt) "uso de cloreto de amônio em terapia"
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
ZA201102211B (en) Improvements in or relating to the management of e-tickets
BR112015006272A2 (pt) ''uso cosmético, composto, composição cosmética e método de tratamento cosmético''
BRDI7102651S (pt) Configuração aplicada em instrumento médico
BR112013007039A2 (pt) "composição de tratamento pessoal"
BR112012025829A2 (pt) ''composição de tratamento, composição líquido e utilização''
FI8286U1 (fi) Kunto- ja terapiaväline
IT1400389B1 (it) Aminaftone per uso nel trattamento e/o nella prevenzione dell'emicrania
IT1397874B1 (it) Uso di peptidi nella terapia antiangiogenica
TH164734B (th) สารประกอบสไพโร-ออกซินโดล และการใช้สารเหล่านี้เป็นสารรักษาโรค

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: PHF SA (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: PHF SA (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: PHF SA (CH)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL